Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
TANG v. EASTMAN KODAK COMPANY et al
Case Number:
3:20-cv-10462
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Akin Gump
- Calcagni & Kanefsky
- Carella Byrne
- Cohn Lifland
- Herman Jones LLP
- Kaplan Fox
- Levi & Korsinsky
- Lite DePalma
- Lowey Dannenberg
- Pomerantz LLP
- Schnader Harrison
Companies
Sectors & Industries:
-
May 28, 2021
Kodak Suit Over Exec Stock Options, $765M Loan Sent To NY
A New Jersey federal judge has sent to the Western District of New York a proposed class action over Eastman Kodak Co.'s award of stock options to executives ahead of a $765 million COVID-19 drug loan announcement, concluding that that forum is the most appropriate venue even though none of the players asked for it.
-
October 14, 2020
12 Firms Vie For Lead In Kodak Investors' Stock Trading Suits
A dozen law firms filed competing motions Tuesday to represent Eastman Kodak Co. shareholders in two proposed class actions in New York and New Jersey federal courts, alleging the former photography giant's executives enriched themselves with stock trading surrounding a $765 million loan from the federal government.
-
August 14, 2020
Kodak Sued Over Execs' Stock Trading Linked To $765M Loan
Eastman Kodak Co. is facing a proposed securities class action one week after the government paused its $765 million COVID-19 drug development loan to the company over "recent allegations of wrongdoing" related to its CEO's stock trading in the days surrounding the deal's announcement.